Nasus Pharma Ltd. (NYSE: NSRX) announced that the first patient has been enrolled and dosed in a Phase 1 pharmacokinetic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE